Key Highlights

  • R&D expense was USD 16.0 million versus 11.0 million, and G&A expense was USD 5.0 million versus 3.9 million.
  • Operating loss was USD 21.0 million versus 14.9 million, and interest income was USD 2.4 million versus 2.0 million.
  • Net loss was USD 18.7 million versus 12.8 million, and net loss per share was USD 0.49 versus 0.45.
  • Cash and cash equivalents were USD 75.2 million and marketable securities were USD 169.3 million at September 30, 2026.

Operating Results

Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical-stage biopharmaceutical company whose lead candidate is PIPE-791, filed its Quarterly Report for the period ended September 30, 2026. Research and Development expense was USD 15,985 thousand, compared with USD 10,992 thousand in the third quarter of 2025. General and administrative expense was USD 4,981 thousand versus USD 3,940 thousand.

Total operating expenses were USD 20,966 thousand versus USD 14,932 thousand, and the loss from operations was the same amount. For the nine months, research and development expense was USD 40,334 thousand versus USD 38,767 thousand, general and administrative expense was USD 14,964 thousand versus USD 12,177 thousand, and the loss from operations was USD 55,298 thousand versus USD 50,944 thousand.

Analyst estimates were EPS of negative USD 0.45 against reported EPS of negative USD 0.49.

Net Loss and Per Share Results

Interest income was USD 2,362 thousand versus USD 1,957 thousand, and other expense, net, was USD 93 thousand compared with other income, net, of USD 183 thousand. Total other income, net, was USD 2,269 thousand versus USD 2,140 thousand.

The net loss was USD 18,697 thousand versus USD 12,792 thousand. The net loss per share, basic and diluted, was USD 0.49 versus USD 0.45, on 38,390,234 weighted-average shares versus 28,115,548. The unrealized loss on marketable securities was USD 934 thousand versus a gain of USD 118 thousand, and the comprehensive loss was USD 19,631 thousand versus USD 12,674 thousand.

For the nine months, the net loss was USD 48,307 thousand versus USD 44,822 thousand, and the net loss per share was USD 1.28 versus USD 1.68.

Cash and Funding

Cash and cash equivalents were USD 75,198 thousand at September 30, 2026, compared with USD 75,603 thousand at December 31, 2025. Marketable securities were USD 169,286 thousand versus USD 187,293 thousand, and total current Assets were USD 249,744 thousand versus USD 267,917 thousand.

Net cash used in Operating Activities for the nine months was USD 38,827 thousand versus USD 42,270 thousand. Purchases of marketable securities were USD 158,946 thousand versus USD 77,769 thousand, and sales and maturities of marketable securities were USD 175,763 thousand versus USD 121,698 thousand.

The company stated that its cash, cash equivalents and marketable securities are sufficient to support operations for at least 12 months from the issuance date of the financial statements. It also stated that it expects to finance its operations through public and private sales of equity, debt financings or other arrangements, including collaborations and strategic partnerships. As of the filing date, 35,353,313 shares of Class A common stock and 3,912,500 shares of Class B common stock were outstanding.

Items to Follow

Investors can follow the clinical development of PIPE-791, which the filing describes as the company's lead drug candidate in early stages of clinical development, and Janssen Pharmaceutica NV's plans related to the clinical development of PIPE-307.

Other items include research and development expense, which was USD 15,985 thousand in the quarter, and the mix of cash and marketable securities as the company pursues its clinical programs.